- We clued in to BioLife a couple of months ago, but we found the valuation a little too steep. That has been taken care of.
- If anything, we see even more potential this time around.
- To boot, the company is already generating positive cash flow and produced its first net profits.
BioLife: Groundfloor Opportunity In Regenerative Medicine
October 30th, 2018 · No Comments